BRPI0619018A2 - composto ou um sal ou solvato farmaceuticamente aceitável do mesmo, uso de um composto, e, composição - Google Patents

composto ou um sal ou solvato farmaceuticamente aceitável do mesmo, uso de um composto, e, composição

Info

Publication number
BRPI0619018A2
BRPI0619018A2 BRPI0619018A BRPI0619018A BRPI0619018A2 BR PI0619018 A2 BRPI0619018 A2 BR PI0619018A2 BR PI0619018 A BRPI0619018 A BR PI0619018A BR PI0619018 A BRPI0619018 A BR PI0619018A BR PI0619018 A2 BRPI0619018 A2 BR PI0619018A2
Authority
BR
Brazil
Prior art keywords
compound
solvate
composition
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
BRPI0619018A
Other languages
English (en)
Inventor
Jeffrey J Hale
Kathleen M Rupprecht
Robert K Baker
Shouwu Miao
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of BRPI0619018A2 publication Critical patent/BRPI0619018A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0619018A 2005-11-28 2006-11-22 composto ou um sal ou solvato farmaceuticamente aceitável do mesmo, uso de um composto, e, composição BRPI0619018A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74018305P 2005-11-28 2005-11-28
PCT/US2006/045328 WO2007062193A1 (en) 2005-11-28 2006-11-22 Heterocycle-substituted 3-alkyl azetidine derivatives

Publications (1)

Publication Number Publication Date
BRPI0619018A2 true BRPI0619018A2 (pt) 2016-11-29

Family

ID=37779312

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0619018A BRPI0619018A2 (pt) 2005-11-28 2006-11-22 composto ou um sal ou solvato farmaceuticamente aceitável do mesmo, uso de um composto, e, composição

Country Status (15)

Country Link
EP (1) EP1954692A1 (pt)
KR (1) KR20080073721A (pt)
AR (1) AR058199A1 (pt)
BR (1) BRPI0619018A2 (pt)
CR (1) CR10014A (pt)
DO (1) DOP2006000261A (pt)
EC (1) ECSP088477A (pt)
IL (1) IL191586A0 (pt)
MA (1) MA30086B1 (pt)
NO (1) NO20082919L (pt)
PE (1) PE20070647A1 (pt)
RU (1) RU2008126248A (pt)
SV (1) SV2009002917A (pt)
TW (1) TW200804317A (pt)
WO (1) WO2007062193A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906652B2 (en) 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CA2703465A1 (en) * 2007-10-24 2009-04-30 Merck Sharp & Dohme Corp. Synthesis and crystalline forms of cb-1 antagonist/inverse agonist
US9440948B2 (en) 2010-09-03 2016-09-13 University Of Florida Research Foundation, Inc. Nicotine compounds and analogs thereof, synthetic methods of making compounds, and methods of use
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2805817B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
FR2805818B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
FR2805810B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation
AU2004252109B2 (en) * 2003-06-11 2010-04-08 Merck Sharp & Dohme Corp. Substituted 3-alkyl and 3-alkenyl azetidine derivatives
AU2006242219A1 (en) * 2005-05-02 2006-11-09 Merck & Co., Inc. Combination of dipeptidyl peptidase-IV inhibitor and a cannabinoid CB1 receptor antagonist for the treatment of diabetes and obesity

Also Published As

Publication number Publication date
ECSP088477A (es) 2008-06-30
PE20070647A1 (es) 2007-08-11
CR10014A (es) 2008-07-29
NO20082919L (no) 2008-08-27
AR058199A1 (es) 2008-01-23
EP1954692A1 (en) 2008-08-13
IL191586A0 (en) 2008-12-29
DOP2006000261A (es) 2007-07-15
KR20080073721A (ko) 2008-08-11
WO2007062193A1 (en) 2007-05-31
RU2008126248A (ru) 2010-01-10
TW200804317A (en) 2008-01-16
MA30086B1 (fr) 2008-12-01
SV2009002917A (es) 2009-02-19

Similar Documents

Publication Publication Date Title
BRPI0607545A2 (pt) composto, uso de um composto de fórmula i ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica
BRPI0516609A (pt) composto ou sal, hidrato, ou estereoisÈmero farmaceuticamente aceitáveis do mesmo, composição farmacêutica, e, uso de um composto
BRPI0609802A2 (pt) composto, composição farmacêutica e uso de um composto
BRPI0818193A2 (pt) composto, sal farmacêuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto
BRPI0614205A2 (pt) composto, composição farmacêutica, e, uso de composto
BRPI0822033A2 (pt) Composto ou sal do mesmo, composição farmacêutica, uso de um composto ou sal, e, kit
BRPI0618904A2 (pt) composto, composição farmacêutica, e, uso do composto
BRPI0917540A2 (pt) composto, sal farmacologicamente aceitavél, composição farmacêutica, e, uso de um composto ou sal farmacologicamente aceitável
BRPI0716171A2 (pt) composto, composiÇço farmacÊutica e uso de um composto.
BRPI0810696A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0815709A2 (pt) composro, composição farmacêutica, e, uso de um composto.
BRPI0716698A2 (pt) Composto, composição farmacêutica e uso de um composto
BRPI0810161A2 (pt) Composto, preparação farmacêutica, composição farmacêutica, e, uso de um composto
IL191759A (en) Ganaxolone formulations and methods for the making and use thereof
BRPI0720637A2 (pt) Composto ou um sal farmaceuticamente aceitável, uma forma estereoisomérica, tautomérica ou polimórfica do mesmo, métodos para o tratamento de um hospedeiro e de tratamento de infecção, composição farmacêutica, e, uso do composto
IL178831A0 (en) Aqueous fungicidal composition and use thereof for combating harmful micro organisms
BRPI0716327A2 (pt) Composto de fenilpropionamida e uso
BRPI0614162A2 (pt) dermocosmético, e, uso de um composto
BRPI0810019A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0812942A2 (pt) Composto, composição farmacêutica e uso de um composto
CR10725A (es) Compuestos de pirazolina y su uso y composiones farmaceuticas
BRPI0813587A2 (pt) Composto, uso do mesmo, e, composição farmacêutica
BRPI0614730A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0716250A2 (pt) Composto ou sal ou solvato do mesmo, composição farmacêutica, método para o tratamento de doenças, e, uso de um composto
BRPI0611025A2 (pt) composto, uso de um composto, e, composição farmacêuticamente aceitável

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO NO ORIGINAL, TRASLADO OU FOTOCOPIA AUTENTICADA.

B11Z Dismissal: petition dismissal - article 216, par 2 of industrial property law

Free format text: REFERENTE A PETICAO NO 20080079731/RJ DE 27/05/2008.

B11M Decision cancelled [chapter 11.13 patent gazette]

Free format text: O DESPACHO 11.6.1 ESTA SENDO ANULADO TENDO POR BASE A DETERMINACAO DO DIRETOR DE PATENTES, A QUAL E CALCADA NO PARECER NO 0003-2014 AGU/PGF/PFE/INPI/COOPHI-LBC-1.0.

B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: O DESPACHO 6.7 ESTA SENDO ANULADO TENDO POR BASE A DETERMINACAO DO DIRETOR DE PATENTES, A QUAL E CALCADA NO PARECER NO 0003-2014 AGU/PGF/PFE/INPI/COOPHI-LBC-1.0.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]